Evaluation of outcomes of clinical phenotyping-based treatment for bladder pain syndrome/interstitial cystitis
Introduction: Bladder pain syndrome/Interstitial cystitis (BPS/IC) is clinically of diverse types because different causes contribute to the development of their symptoms. It is important to classify patients into various groups based on the possible etiopathogenesis of their condition. Treatment may be tailored to each specific group according to the possible cause. Methodology: Twenty-five patients diagnosed with BPS/IC were categorized into four different clinical phenotypes (CP) based on their history of symptoms, allergy, dysfunctional voiding, neuropathic pain, and the presence of Hunner’s ulcer. Some patients could be classified into multiple groups. The patients were given oral pentosan polysulfate, and treatment specific to their CP. Patients in CP1, CP2, and CP3 groups received, respectively hydroxyzine, clonazepam, and amitriptyline. Patients with Hunner’s lesions (HL) (CP4) underwent hydro distension and ablation of the lesion, followed by intravesical instillation of heparin and hydrocortisone. The patients were evaluated using the Apollo clinical scoring (ACS) system and their clinical scores were recorded at 1, 3, and 6 month(s). Results: Among the 25 patients, 5, 7, 4, and 9 patients were classified into CP 1 – CP4 groups respectively, and were all subjected to ACS assessment. In CP1 group (allergy group), 80% (4/5) of patients responded well to the treatment and 20% (1/5) had unsatisfactory responses. In CP2 group (dysfunctional voiding group), 71.42% (5/7) patients had good, and 28.57% (2/7) had excellent responses. In CP3 group (neuropathic pain group), 28.57% (3/4) patients had excellent, and 75% (1/4) patients had good responses. In CP4 group (HL group), 33.33% (3/9) patients had unsatisfactory, 44.44% (4/9) achieved good, and 22.22% (2/9) had excellent responses. Overall, 16% (4/25) patients had unsatisfactory, 56% (14/25) attained good, and 28% (7/25) had an excellent response at the completion of the study. Conclusion: Using clinical phenotyping-based features indicative of etiology could potentially improve treatment outcomes by targeting the specific pathological processes contributing to the patients’ symptoms.
- Van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur Urol. 2008;53(1):60-67. doi: 10.1016/j.eururo.2007.09.019
- Hanno PM, Nordling J, Staskin DR, et al. Bladder Pain Syndrome-An Evolution. USA: Springer; 2018.
- Barone B, De Luca L, Napolitano L, et al. Lower urinary tract symptoms and mental health during COVID-19 pandemic. Arch Ital Urol Androl. 2022;94(1):46-50. doi: 10.4081/aiua.2022.1.46
- Taneja R, Chugh DK. Clinical phenotyping linked treatment strategies in patients with bladder pain syndrome. Urol Nephrol Open Access J. 2020;8(4):93-97. doi: 10.15406/unoaj.2020.08.00283
- Taneja R. Current status of oral pentosan polysulphate in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2020;32:1107-1115.
- Minogiannis P, El-Mansoury M, Betances JA, Sant GR, Theoharides TC. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunopharmacol. 1998;20:553-563. doi: 10.1016/s0192-0561(98)00054-x
- Theoharides TC, Sant GR. Hydroxyzine therapy for interstitial cystitis. Urology. 1997;49:108-110. doi: 10.1016/s0090-4295(97)00182-9
- Sant GR, Propert KJ, Hanno PM, et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003;170:810-815. doi: 10.1097/01.ju.0000083020.06212.3d
- Van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172:533-536. doi: 10.1097/01.ju.0000132388.54703.4d
- Van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol. 2005;174:1837-1840. doi: 10.1097/01.ju.0000176741.10094.e0
- Hanno PM. Amitriptyline in the treatment of interstitial cystitis. Urol Clin North Am. 1994;21:89-91.
- Taneja R, Jawade K. A rational combination of intravesical and systematic agents in the treatment of interstitial cystitis. Scand J Nephrol Urol. 2007;41(6):511-515. doi: 10.1080/00365590701435918
- Nickel JC, Shoskes D, Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: A key to classification and potentially improved management. J Urol. 2009;182(1):155-160. doi: 10.1016/j.juro.2009.02.122
- Taneja R, Pandey S, Priyadarshi S, et al. Diagnostic and therapeutic cystoscopy in bladder pain syndrome/interstitial cystitis: Systematic review of literature and consensus on methodology. Int Urogynecol J. 2023;34:1165-73. doi: 10.1007/s00192-023-05449-w
- Crocetto F, Balsamo R, Amicuzi U, et al. Novel key ingredients in urinary tract health-the role of d-mannose, chondroitin sulphate, hyaluronic acid, and n-acetylcysteine in urinary tract infections (Uroial PLUS®). Nutrients. 2023;15(16):3573. doi: 10.3390/nu15163573
- Taneja R, Massand S. A modified clinical scoring system for bladder pain syndrome: Long term experience. Int J Urol. 2019;26:61-7. doi: 10.1111/iju.13977
- Malde S, Sahai A. Phenotypes of BPS/IC. Curr Bladder Dysfunct Rep. 2020;15:203-213.
- Fall M, Nordling J, Cervigni M, et al. Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: An ESSIC working group report. Scand J Urol. 2020;54(2):91-98. doi: 10.1080/21681805.2020.1730948
- Gupta P, Gaines N, Sirls LT, et al. A multidisciplinary approach to the evaluation and management of interstitial cystitis/ bladder pain syndrome: An ideal model of care. Transl Androl Urol. 2015;4(6):611-619. doi: 10.3978/j.issn.2223-4683.2015.10.10
- Whitmore KE, Fall M, Sengiku A, Tomoe H, Logadottir Y, Kim YH. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26 Suppl 1: 26-34. doi: 10.1111/iju.13971
- Hanno PM, Burks DA, Clemens Q, et al. American urological association (AUA) guideline. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2014;185:60-67.
- Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: A management strategy for urologic chronic pelvic pain syndromes. Prostate cancer Prostatic Dis. 2009;12(20):177-183. doi: 10.1038/pcan.2008.42
- Doiron RC, Tolls V, Irvine-Bird K, et al. Clinical phenotyping does not differentiate hunner lesion subtype of interstitial cystitis/bladder pain syndrome: A relook at the role of cystoscopy. J Urol. 2016;196(4):1136-1140. doi: 10.1016/j.juro.2016.04.067
- Malykhina A, Hanno P. How are we going to make progress treating bladder pain syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):625-659. doi: 10.1002/nau.22575
- Lai HH, Pickersgill NA, Vetter JM. Phenotype in interstitial cystitis/bladder pain syndrome: A systematic review and meta-analysis. J Urol. 2020;204:518-523. doi: 10.1097/JU.0000000000001031
- Ogawa T, Ishizuka O, Ueda T, et al. Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). Expert Opin Emerg Drugs. 2015;20(4):555-570. doi: 10.1517/14728214.2015.1105216
- Nardelli C, Aveta A, Pandolfo SD, et al. Microbiome profiling in bladder cancer patients using the first-morning urine sample. Eur Urol Open Sci. 2023;59:18-26. doi: 10.1016/j.euros.2023.11.003